| First Author | Hequet O | Year | 2020 |
| Journal | Eur J Immunol | Volume | 50 |
| Issue | 5 | Pages | 725-735 |
| PubMed ID | 32012249 | Mgi Jnum | J:288848 |
| Mgi Id | MGI:6416351 | Doi | 10.1002/eji.201948318 |
| Citation | Hequet O, et al. (2020) CD8(+) T cells mediate ultraviolet A-induced immunomodulation in a model of extracorporeal photochemotherapy. Eur J Immunol 50(5):725-735 |
| abstractText | Extracorporeal photochemotherapy (ECP) that takes advantage of the immunomodulatory effects of UV light has been extensively used for many years for the treatment of several T cell-mediated diseases, including graft-versus-host disease (GvHD) and systemic scleroderma. Immune mechanisms that lead to the establishment of T cell tolerance in ECP-treated patients remain poorly known. In this study, we have tested the effect of UV/psoralen-treated BM-derived dendritic cells, referred to as ECP-BMDCs on the outcome of an antigen-specific T cell-mediated reaction, that is, contact hypersensitivity (CHS), which is mediated by CD8(+) effector T cells (CD8(+) Teff ). The intravenous (i.v.) injection of antigen-pulsed ECP-BMDCs in recipient C57BL/6 mice induced specific CD8(+) T cells endowed with immunomodulatory properties (referred to as CD8(+) TECP ), which prevented the priming of CD8(+) Teff and the development of CHS, independently of conventional CD4(+) regulatory T cells. CD8(+) TECP mediated tolerance by inhibiting the migration and functions of skin DC and subsequently the priming of CD8(+) Teff . CD8(+) TECP displayed none of the phenotypes of the usual CD8(+) T regulatory cells described so far. Our results reveal an underestimated participation of CD8(+) T cells to ECP-induced immunomodulation that could explain the therapeutic effects of ECP in T cell-mediated diseases. |
